On September 26, 2025, Cosmos Health Inc. announced that its wholly‑owned subsidiary Cana Laboratories S.A. signed a contract manufacturing agreement with Medical Pharmaquality S.A. for the production of MYCOFAGYL® pessaries. The agreement will see Cana manufacture and deliver 3 million pessaries per year, each pack containing 10 units of the dual‑action drug combining 500 mg Metronidazole and 100,000 IU Nystatin.
The deal expands Cana’s portfolio into the women’s health sector, adding a high‑margin product to its existing gynecology, infectious‑disease, and other therapeutic lines. The contract is expected to generate significant cash flow and strengthen the company’s contract‑manufacturing pipeline, which has been a key revenue driver in recent quarters.
For investors, the agreement represents a tangible revenue source that could improve COSG’s liquidity profile amid ongoing working‑capital challenges. The 3‑million‑unit annual volume also positions the company to capture a share of the global vaginal‑infection treatment market, potentially boosting future earnings.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.